Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at SunTrust Banks lowered their Q3 2017 earnings per share estimates for Agios Pharmaceuticals in a research note issued to investors on Tuesday. SunTrust Banks analyst Y. Suneja now expects that the biopharmaceutical company will earn ($1.78) per share for the quarter, down from their prior forecast of ($1.64). SunTrust Banks currently has a “Buy” rating and a $80.00 target price on the stock. SunTrust Banks also issued estimates for Agios Pharmaceuticals’ Q4 2017 earnings at ($1.77) EPS, FY2017 earnings at ($6.92) EPS, FY2019 earnings at ($5.80) EPS, FY2020 earnings at ($4.90) EPS and FY2021 earnings at ($1.80) EPS.
Several other analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Janney Montgomery Scott lowered shares of Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, May 4th. Cann reiterated a “buy” rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Finally, ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $68.67.
WARNING: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/08/10/agios-pharmaceuticals-inc-to-post-q3-2017-earnings-of-1-78-per-share-suntrust-banks-forecasts-agio.html.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) opened at 60.56 on Thursday. Agios Pharmaceuticals has a 1-year low of $35.84 and a 1-year high of $67.74. The company’s 50-day moving average is $56.81 and its 200 day moving average is $51.69. The firm’s market cap is $2.92 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($1.57) by $0.21. The business had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 75.48% and a negative net margin of 502.12%. Agios Pharmaceuticals’s revenue was up 62.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.47) EPS.
In related news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $47.10, for a total transaction of $95,895.60. Following the completion of the transaction, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David P. Schenkein sold 3,000 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $50.02, for a total transaction of $150,060.00. Following the transaction, the chief executive officer now directly owns 1,100 shares of the company’s stock, valued at $55,022. The disclosure for this sale can be found here. Insiders have sold a total of 79,120 shares of company stock valued at $4,557,207 over the last three months. 10.55% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in AGIO. BlackRock Inc. increased its position in shares of Agios Pharmaceuticals by 8,463.5% in the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after buying an additional 2,141,768 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Agios Pharmaceuticals by 748.0% in the first quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after buying an additional 572,579 shares in the last quarter. First Trust Advisors LP increased its position in shares of Agios Pharmaceuticals by 52.3% in the second quarter. First Trust Advisors LP now owns 973,870 shares of the biopharmaceutical company’s stock worth $50,106,000 after buying an additional 334,291 shares in the last quarter. Norges Bank bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth $8,246,000. Finally, Redmile Group LLC increased its position in shares of Agios Pharmaceuticals by 22.2% in the first quarter. Redmile Group LLC now owns 902,578 shares of the biopharmaceutical company’s stock worth $52,711,000 after buying an additional 164,127 shares in the last quarter. 84.53% of the stock is owned by hedge funds and other institutional investors.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.